CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Cipla partners with MSD to manufacture COVID-19 antiviral drug Molnupiravir
Shruti Dahiwal
/ Categories: Trending

Cipla partners with MSD to manufacture COVID-19 antiviral drug Molnupiravir

Cipla Limited, a global pharmaceutical company, announced this afternoon that it has entered into a non-exclusive licensing agreement with Merck & Co, Inc (MSD) for the manufacturing & distribution of Molnupiravir.  

Molnupiravir is the investigational oral antiviral drug currently being studied in a phase 3 trial for the treatment of non-hospitalised COVID-19 patients. MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics. This agreement is aligned with Cipla’s efforts to enhance global access to treatments for COVID-19 patients.   

As a part of the agreement, Cipla will be permitted to manufacture, market & distribute Molnupiravir in India and in more than 100 low-income & middle-income countries. Cipla’s strong foothold across the globe will help make this therapy accessible to more patients and markets.  

Umang Vohra (MD & Global CEO, Cipla Limited) says, “Cipla continues to remain at the forefront in its fight against COVID-19. As we are hit by the second wave, it is pivotal for us to embrace the power of collaboration in order to combat the threat to human life. We are pleased to partner with MSD for this cause and take this treatment to patients across countries. In keeping with our purpose of caring for life, this collaboration will expand patient access to quality treatment for COVID-19.”  

At 3.37 pm, the share price of Cipla Limited was trading at Rs 908.50 on BSE, which was a decrease of 0.41 per cent over its previous day’s closing price of Rs 912.25. 

Previous Article Aurionpro subsidiary & Mastercard enter into strategic alliance; stock climbs almost 6 per cent
Next Article Demystifying trading range
Print
833 Rate this article:
3.8
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR